The project aims to further investigations of biomarkers for unstableatherosclerosis.
Cardiovascular disease is one of the main causes of deaths in the western world, killing over 2 million people annually. Prevention, through constant monitoring of heart health, is considered the best way to tackle the problem. The cardiovascular market size will exceed USD 3 billion in 2018.
MetaboGen is a biomarker and personalized treatment company using proprietary metagenomic phenotyping of the gut microbiota to identify new biomarkers, develop novel diagnostic tests
and related treatment options. The awarded project will be performed in collaboration with Chalmers University of Technology, Sahlgrenska University hospital in Gothenburg and GU Holding AB.
- Göteborgs universitet (Akademisk, Sweden)
- Göteborgs universitet (Utgivare, Sweden)
- MetaboGen (Privat, Sweden)
Projektet är avslutat: 2015-06-15